In clinical practice, the measurement of CEA proved to be a well-established biomarker, most useful in determining distant metastases [24] and monitoring the metastatic disease’s response to systemic therapy and detecting the recurrence of CRC [25]. The gene discussed is CEACAM5; the disease is colorectal carcinoma.